Please assess the completion status of the following clinical trial:

Trial Title: Pre-Prostatectomy Celecoxib or Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histopathologically or cytologically proven adenocarcinoma of the prostate and planned prostatectomy~* Age \>= 18~* Performance status (ECOG \<= 2)~* Hemoglobin \> 10 g/dL (within 4 weeks)~* Creatinine \<= 1.5 mg/dL~* Signed informed patient consent~Exclusion Criteria:~* Other preoperative or prior treatment directed at prostate cancer~* Significant active medical illness which in the opinion of the investigator would preclude protocol treatment~* Use of non-steroidal anti-inflammatory agents within seven days of celecoxib treatment~* Hypersensitivity to celecoxib~* A history of asthma, urticaria, or anaphylaxis precipitated by an NSAID~* History of significant upper gastrointestinal bleeding or active peptic ulcer disease~* Current treatment with anticoagulants~* Allergy to sulfonamide

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Celecoxib (Type: ACTIVE_COMPARATOR): Treated patients will receive 4 weeks of celecoxib at 400 mg twice daily by mouth
- Placebo (Type: PLACEBO_COMPARATOR): Control patients will receive a suitable placebo for 4 weeks, twice daily by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).